Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits

JACC: Heart Failure

Volumn 5, Issue 8, 2017, Pages 591-599

  Shen, Li ^a   Jhund, Pardeep S ^a   Mogensen, Ulrik M ^a,b   Køber, Lars ^b   Claggett, Brian ^c   Rogers, Jennifer K ^d   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Rigshospitalet   (Denmark)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

BEST; endpoint; heart failure; recurrent events

Indexed keywords

BUCINDOLOL; PLACEBO; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPANOLAMINE DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EMERGENCY WARD; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; BIOASSAY; CLINICAL TRIAL; HOSPITAL EMERGENCY SERVICE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RECURRENT DISEASE; SAMPLE SIZE; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UTILIZATION;

ADRENERGIC BETA-ANTAGONISTS; DOUBLE-BLIND METHOD; EMERGENCY SERVICE, HOSPITAL; ENDPOINT DETERMINATION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPANOLAMINES; RECURRENCE; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 85026544019     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.04.005     Document Type: Article

References (29)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987), 1429–1435.
2. SOLVD Investigators, Yusuf, S., Pitt, B., Davis, C.E., Hood, W.B., Cohn, J.N., Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302.
3. Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999), 709–717.
4. Neaton, J.D., Gray, G., Zuckerman, B.D., Konstam, M.A., Key issues in end point selection for heart failure trials: composite end points. J Card Fail 11 (2005), 567–575.
5. Anker, S.D., Schroeder, S., Atar, D., et al. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. Eur J Heart Fail 18 (2016), 482–489.
6. Stewart, S., Jenkins, A., Buchan, S., McGuire, A., Capewell, S., McMurray, J.J., The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 4 (2002), 361–371.
7. Rush, C.J., Campbell, R.T., Jhund, P.S., et al. Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. J Am Coll Cardiol HF 3 (2015), 603–614.
8. Jhund, P.S., Macintyre, K., Simpson, C.R., et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 119 (2009), 515–523.
9. Schaufelberger, M., Swedberg, K., Koster, M., Rosen, M., Rosengren, A., Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J 25 (2004), 300–307.
10. Rogers, J.K., Jhund, P.S., Perez, A.C., et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2 (2014), 289–297.
11. Rogers, J.K., Pocock, S.J., McMurray, J.J., et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail 16 (2014), 33–40.
12. Rogers, J.K., McMurray, J.J., Pocock, S.J., et al. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation 126 (2012), 2317–2323.
13. Anker, S.D., McMurray, J.J., Time to move on from 'time-to-first': should all events be included in the analysis of clinical trials?. Eur Heart J 33 (2012), 2764–2765.
14. Goldenberg, I., Hall, W.J., Beck, C.A., et al. Reduction of the risk of recurring heart failure events with cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Am Coll Cardiol 58 (2011), 729–737.
15. Skali, H., Dwyer, E.M., Goldstein, R., et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail 16 (2014), 560–565.
16. Okumura, N., Jhund, P.S., Gong, J., et al. Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation 133 (2016), 2254–2262.
17. Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee. Am J Cardiol 75 (1995), 1220–1223.
18. Beta-Blocker Evaluation of Survival Trial Investigators, Eichhorn, E.J., Domanski, M.J., Krause-Steinrauf, H., Bristow, M.R., Lavori, P.W., A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344 (2001), 1659–1667.
19. Domanski, M.J., Krause-Steinrauf, H., Massie, B.M., et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail 9 (2003), 354–363.
20. O'Connor, C.M., Fiuzat, M., Carson, P.E., et al. Combinatorial pharmacogenetic interactions of bucindolol and beta1, alpha2C adrenergic receptor polymorphisms. PLoS One, 7, 2012, e44324.
21. Taylor, M.R., Sun, A.Y., Davis, G., Fiuzat, M., Liggett, S.B., Bristow, M.R., Race, common genetic variation, and therapeutic response disparities in heart failure. J Am Coll Cardiol HF 2 (2014), 561–572.
22. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999), 9–13.
23. Hjalmarson, A., Goldstein, S., Fagerberg, B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. JAMA 283 (2000), 1295–1302.
24. Packer, M., Fowler, M.B., Roecker, E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002), 2194–2199.
25. Bristow, M.R., Krause-Steinrauf, H., Nuzzo, R., et al. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation 110 (2004), 1437–1442.
26. Lee, D.S., Schull, M.J., Alter, D.A., et al. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail 3 (2010), 228–235.
27. Ezekowitz, J.A., Kaul, P., Bakal, J.A., Quan, H., McAlister, F.A., Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics?. Eur J Heart Fail 13 (2011), 142–147.
28. Liggett, S.B., Mialet-Perez, J., Thaneemit-Chen, S., et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A 103 (2006), 11288–11293.
29. Carson, P., Fiuzat, M., O'Connor, C., et al. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (beta-Blocker Evaluation of Survival Trial [BEST]). Am Heart J 160 (2010), 649–654.